182 related articles for article (PubMed ID: 34122070)
1. Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia.
Liu W; Wang B; Zhao Y; Wu Z; Dong A; Chen H; Lin L; Lu J; Hai X
Front Pharmacol; 2021; 12():647687. PubMed ID: 34122070
[TBL] [Abstract][Full Text] [Related]
2. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.
Guo M; Lv J; Chen X; Wu M; Zhao Q; Hai X
Front Oncol; 2022; 12():887026. PubMed ID: 35646703
[TBL] [Abstract][Full Text] [Related]
3. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
5. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.
Guo M; Wang W; Hai X; Zhou J
J Pharm Biomed Anal; 2017 Oct; 145():356-363. PubMed ID: 28711674
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
8. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
9. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
[TBL] [Abstract][Full Text] [Related]
10. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of arsenic species after oral administration of Sargassum pallidum extract in rats using an HPLC-HG-AFS method.
Cao Y; Duan J; Guo J; Li W; Tao W
J Pharm Biomed Anal; 2014 Aug; 96():213-9. PubMed ID: 24763266
[TBL] [Abstract][Full Text] [Related]
12. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
13. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
15. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
16. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
17. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
18. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
19. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
[TBL] [Abstract][Full Text] [Related]
20. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
